CryoLife, Inc.
HCID Member | Medical Devices & Tech  Advamed Member
1655 Roberts Boulevard N.W.
Kennesaw, GA 30144 USA
phone: (770) 419-3355
fax: 770-426-0031
Symbol CRY
Exchange NYSE
Founded 1984
Employees 405
www.cryolife.com
Research Sector Medical Devices & Tech
Summary Description
Implantable biological devices, surgical adhesives, and biomaterials for use in surgical procedures
Management
Steven G. Anderson, Chairman, President and Chief Executive Officer
Ownership
Financials Mkt Cap :375


* numbers in thousands

 
Keywords
Cardiology, Heart Valves, Vascular Grafts, Adhesives, Sealants, Hemostats

Comment | Printable Version | Nov. 17, 2008
If you work for CryoLife, Inc. and want to update this profile, click here

Description
CryoLife, a contemporary biological medical device company, specializes in the development of implantable biological devices, surgical adhesives, and biomaterials for use in cardiac and vascular surgery. The company operates in two distinct but synergistic segments, one focused on products and the other focused on services
Products / Services
CryoLife's human tissue preservation service draws revenue through cardiac and vascular allograft tissue preservation. A substantial portion of CryoLife's R&D efforts are focused on Protein Hydrogel Technologies, including BioFoam for severe wounds and the BioDisc for spinal repair. BioGlue is a biosurgical device which helps control bleeding in open surgical repair of large vessels.
Technology / Differentiation
BioGlue is the first Protein Hydrogel Technologies product to be commercially introduced into world markets. BioGlue is a two-component surgical adhesive designed for cardiovascular, vascular, pulmonary, and general surgical applications.
Market / Customers
Over 75% of all cardiovascular procedures involving allograft (homograft) tissue in the U.S. are performed with cryopreserved human heart valves from CryoLife. The company distributes its tissue to implantation institution is the U.S., Canada and Europe. BioGlue is used by surgeons to reinforce friable, diseased, or damaged tissues, such as cardiac and vascular tissue. CryoLife distributes BioGlue in more than 60 countries worldwide.
Strategy
Aurazyme Pharmaceuticals, a wholly owned subsidiary of CryoLife, is focusing on the development of novel drug therapies for cardiovascular and cancer treatment.
Status
CryoLife's R&D efforts are focused on Protein Hydrogel Technologies (BioDisc for spinal repair and BioFoam for abdominal aortic aneurysms and severe wounds) and Antigen Reduction Technologies (bovine conduit for arteriovenous access). BioGlue is approved in the U.S. for use in adult patients as an adjunct to standard methods, such as sutures and staples. It is approved in the European Community and Canada as an adjunct to surgical repair for soft tissues.


2008-11-23-1656